Natural product-derived therapy for Metastatic cancers: Dihydroartemisinin (DHA), a derivative of Artemisinin isolated from Artemisia Annua L, increases the expression of metastasis promoters TIMP3 and CCM3/KRIT1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 29/June/2017, 11.56 pm pm

Natural product-derived therapy for Chronic Myeloid leukaemia (CML): Curcumin, isolated from Turmeric, decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 29/May/2017, 11.56 pm
June 29, 2017
Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Artesunate, a derivative of Artemisinin isolated from Artemisia Annua, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 29/May/2017, 11.58 pm
June 29, 2017
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

A number of studies suggests that natural-product derived compound Dihydroartemisinin (DHA) inhibits tumor cell proliferation. However, the mechanism of action is far from clear.

This study suggests that Dihydroartemisinin (DHA), by regulating the expression of its target genes, it may increase the expression of metastasis suppressors TIMP3 (TIMP metallopeptidase inhibitor 3) and CCM3/KRIT1 (Cerebral cavernous malformation 3 ortholog) (fig. 1).

[easy_payment currency=”USD”]

Fig1. Mechanistic insights into how Dihydroartemisinin (DHA) functions as an anti-metastasis agent. Dihydroartemisinin (DHA) increases the expression of metastasis suppressors TIMP3 and CCM3/KRIT1 via down regulation of its target genes.

Thereby, it may: (a) inhibit cell cycle progression; and (d) suppress migration, invasion and metastasis of cancer cells. Thus, pharmacological formulations encompassing “Dihydroartemisinin (DHA) or its analogs,  either alone or in combination with other anticancer drugs” may be used to inhibit the progression of invasive tumors.


Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $2

Undisclosed mechanistic information: How Dihydroartemisinin (DHA) increases the expression of metastasis suppressors  TIMP3 and CCM3/KRIT1

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org


References

CitationBoominathan, L., Natural product-derived therapy for Metastatic cancers: Dihydroartemisinin (DHA), a derivative of Artemisinin isolated from Artemisia Annua L, increases the expression of metastasis promoters TIMP3 and CCM3/KRIT1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 29/June/2017, 11.57 pm pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.